Clinical Trial Update: Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study results show activity and safety of pralsetinib in RET-altered cancers, including non-small cell lung cancer and thyroid cancers, with completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Non-small Cell Lung Cancer
• Papillary Thyroid Carcinoma

Drugs mentioned

• GAVRETO (pralsetinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-31